|
|
|
Originator Org.- |
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.JP |
First Approval Date04 Jun 1981 |
An open, Randomized, Multi-centered Phase III study on the efficacy and safety of CreaVax-RCC Inj. (Autologous Mature Dendritic Cells) versus Sorafenib tosylate in patients with metastatic renal cell carcinoma.
100 Clinical Results associated with JW SHINYAK Corp.
0 Patents (Medical) associated with JW SHINYAK Corp.
100 Deals associated with JW SHINYAK Corp.
100 Translational Medicine associated with JW SHINYAK Corp.